Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Cirrhosis | 18 | 2022 | 819 | 4.100 |
Why?
|
| Liver Transplantation | 16 | 2024 | 1007 | 1.810 |
Why?
|
| End Stage Liver Disease | 6 | 2020 | 177 | 1.560 |
Why?
|
| Carcinoma, Hepatocellular | 16 | 2022 | 927 | 1.470 |
Why?
|
| Liver Neoplasms | 15 | 2022 | 1300 | 1.280 |
Why?
|
| Quality Indicators, Health Care | 5 | 2024 | 213 | 1.080 |
Why?
|
| Waiting Lists | 8 | 2024 | 224 | 0.920 |
Why?
|
| Hepatitis C, Chronic | 4 | 2019 | 319 | 0.840 |
Why?
|
| Antiviral Agents | 4 | 2019 | 731 | 0.790 |
Why?
|
| Insurance, Health | 2 | 2019 | 136 | 0.770 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2022 | 164 | 0.720 |
Why?
|
| Social Discrimination | 1 | 2019 | 5 | 0.690 |
Why?
|
| Tissue Donors | 3 | 2017 | 496 | 0.680 |
Why?
|
| Patient Selection | 5 | 2019 | 684 | 0.650 |
Why?
|
| Reimbursement Mechanisms | 1 | 2019 | 38 | 0.630 |
Why?
|
| Disease Management | 2 | 2014 | 514 | 0.620 |
Why?
|
| Health Equity | 1 | 2019 | 54 | 0.610 |
Why?
|
| Liver Diseases | 1 | 2022 | 362 | 0.610 |
Why?
|
| alpha-Fetoproteins | 4 | 2021 | 131 | 0.600 |
Why?
|
| Quality Improvement | 2 | 2022 | 621 | 0.600 |
Why?
|
| Models, Theoretical | 2 | 2019 | 351 | 0.560 |
Why?
|
| Cost of Illness | 3 | 2018 | 242 | 0.550 |
Why?
|
| Frailty | 4 | 2021 | 97 | 0.500 |
Why?
|
| United States | 17 | 2024 | 10559 | 0.480 |
Why?
|
| Drug Approval | 1 | 2014 | 39 | 0.460 |
Why?
|
| Ascites | 3 | 2019 | 87 | 0.450 |
Why?
|
| Quality of Life | 2 | 2022 | 1921 | 0.440 |
Why?
|
| Patient Readmission | 1 | 2017 | 364 | 0.430 |
Why?
|
| Health Services Administration | 1 | 2012 | 12 | 0.420 |
Why?
|
| Quality of Health Care | 2 | 2014 | 391 | 0.420 |
Why?
|
| Tissue and Organ Procurement | 2 | 2012 | 218 | 0.400 |
Why?
|
| Retirement | 1 | 2012 | 18 | 0.390 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 134 | 0.390 |
Why?
|
| Hepatitis C | 2 | 2019 | 365 | 0.380 |
Why?
|
| Humans | 43 | 2024 | 122633 | 0.360 |
Why?
|
| Hospitals, Veterans | 1 | 2012 | 355 | 0.340 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 208 | 0.330 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 347 | 0.330 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2014 | 710 | 0.320 |
Why?
|
| Resource Allocation | 1 | 2008 | 52 | 0.310 |
Why?
|
| Policy Making | 1 | 2008 | 58 | 0.310 |
Why?
|
| Medicare | 1 | 2012 | 423 | 0.310 |
Why?
|
| Liver Failure | 1 | 2008 | 89 | 0.300 |
Why?
|
| Public Health | 1 | 2009 | 254 | 0.290 |
Why?
|
| Caregivers | 1 | 2012 | 563 | 0.270 |
Why?
|
| Health Personnel | 1 | 2011 | 500 | 0.270 |
Why?
|
| Graft Rejection | 1 | 2008 | 582 | 0.240 |
Why?
|
| Biomarkers | 1 | 2012 | 2935 | 0.220 |
Why?
|
| Hepatic Encephalopathy | 3 | 2019 | 74 | 0.200 |
Why?
|
| Delphi Technique | 2 | 2024 | 200 | 0.200 |
Why?
|
| Time Factors | 9 | 2019 | 6188 | 0.200 |
Why?
|
| Risk Factors | 9 | 2021 | 9943 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 1248 | 0.190 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2012 | 79 | 0.190 |
Why?
|
| Adult | 14 | 2021 | 28881 | 0.190 |
Why?
|
| Civil Rights | 1 | 2019 | 10 | 0.170 |
Why?
|
| Male | 18 | 2020 | 59714 | 0.170 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 223 | 0.170 |
Why?
|
| Policy | 1 | 2019 | 34 | 0.170 |
Why?
|
| Prisoners | 1 | 2019 | 33 | 0.170 |
Why?
|
| Religion | 1 | 2019 | 49 | 0.160 |
Why?
|
| Female | 18 | 2020 | 65117 | 0.160 |
Why?
|
| Liver | 2 | 2020 | 1725 | 0.160 |
Why?
|
| Clinical Decision-Making | 2 | 2018 | 266 | 0.160 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2018 | 35 | 0.150 |
Why?
|
| Palliative Care | 1 | 2022 | 428 | 0.150 |
Why?
|
| Markov Chains | 4 | 2010 | 80 | 0.150 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2018 | 64 | 0.150 |
Why?
|
| Middle Aged | 13 | 2020 | 25849 | 0.150 |
Why?
|
| Alcoholism | 1 | 2019 | 228 | 0.140 |
Why?
|
| Alcohol Drinking | 1 | 2019 | 337 | 0.140 |
Why?
|
| Donor Selection | 1 | 2017 | 52 | 0.140 |
Why?
|
| Aged | 9 | 2019 | 18982 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 606 | 0.140 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 280 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 171 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 172 | 0.130 |
Why?
|
| Health Status | 2 | 2018 | 373 | 0.120 |
Why?
|
| Health Care Reform | 1 | 2014 | 50 | 0.120 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 923 | 0.120 |
Why?
|
| Survival Rate | 2 | 2008 | 1992 | 0.110 |
Why?
|
| Bile Duct Diseases | 1 | 2012 | 17 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 1114 | 0.100 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 2100 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2019 | 15916 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2018 | 1162 | 0.100 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2011 | 11 | 0.090 |
Why?
|
| Algorithms | 1 | 2018 | 1583 | 0.090 |
Why?
|
| Benchmarking | 2 | 2022 | 131 | 0.090 |
Why?
|
| Disability Evaluation | 1 | 2012 | 190 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 5019 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 1148 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 11 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2012 | 383 | 0.090 |
Why?
|
| Young Adult | 5 | 2018 | 8817 | 0.090 |
Why?
|
| Prevalence | 2 | 2018 | 2388 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2017 | 977 | 0.090 |
Why?
|
| Incidence | 3 | 2012 | 3040 | 0.080 |
Why?
|
| Medicaid | 1 | 2012 | 242 | 0.080 |
Why?
|
| Cholestasis | 1 | 2011 | 148 | 0.080 |
Why?
|
| Patient Participation | 1 | 2011 | 218 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1306 | 0.080 |
Why?
|
| Medical Informatics | 1 | 2010 | 107 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2012 | 364 | 0.080 |
Why?
|
| Self Care | 1 | 2010 | 210 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 2837 | 0.080 |
Why?
|
| Hospitalization | 1 | 2017 | 1730 | 0.080 |
Why?
|
| Health Behavior | 1 | 2011 | 378 | 0.080 |
Why?
|
| Pyridines | 1 | 2010 | 222 | 0.080 |
Why?
|
| Hepacivirus | 1 | 2009 | 241 | 0.070 |
Why?
|
| Viral Load | 1 | 2009 | 382 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2019 | 12055 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2012 | 3648 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2012 | 6341 | 0.070 |
Why?
|
| Comorbidity | 1 | 2012 | 1491 | 0.070 |
Why?
|
| Mass Screening | 1 | 2012 | 786 | 0.070 |
Why?
|
| Graft Survival | 1 | 2008 | 524 | 0.070 |
Why?
|
| Disease Progression | 2 | 2011 | 2024 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2010 | 1164 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2012 | 3256 | 0.060 |
Why?
|
| Prognosis | 3 | 2011 | 4488 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 821 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2019 | 3316 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2012 | 6012 | 0.060 |
Why?
|
| Michigan | 2 | 2012 | 39 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2024 | 350 | 0.050 |
Why?
|
| Registries | 2 | 2018 | 1379 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 1675 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 83 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2018 | 14 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2019 | 41 | 0.040 |
Why?
|
| North America | 1 | 2019 | 234 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 2018 | 35 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 294 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 416 | 0.040 |
Why?
|
| Survivors | 2 | 2010 | 345 | 0.040 |
Why?
|
| Age Factors | 2 | 2017 | 2788 | 0.040 |
Why?
|
| Patient Dropouts | 1 | 2017 | 49 | 0.040 |
Why?
|
| Mobile Applications | 1 | 2018 | 91 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2010 | 1466 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2012 | 944 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 2017 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2012 | 284 | 0.020 |
Why?
|
| Transplantation, Heterotopic | 1 | 2011 | 29 | 0.020 |
Why?
|
| Perception | 1 | 2011 | 216 | 0.020 |
Why?
|
| Niacinamide | 1 | 2010 | 24 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2010 | 88 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2010 | 48 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2010 | 105 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 439 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 1240 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 465 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1411 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 1242 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 757 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 498 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1787 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2009 | 458 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 4686 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 12272 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2017 | 13794 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 18987 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2011 | 2996 | 0.010 |
Why?
|
| Child | 1 | 2017 | 24086 | 0.010 |
Why?
|